| |
| |
|
| Insider
Information: |
Mackay Martin |
| Relationship: |
Chief Executive Office... |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
720,872 |
|
|
Indirect Shares
|
450,645 |
|
|
| Direct
Value |
$23,096,151 |
|
|
|
Indirect Value
|
$418,189 |
|
|
| Total
Shares |
1,171,517 |
|
|
| Total
Value |
$23,514,340 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pfizer Inc |
PFE |
Senior Vice President |
2010-02-25 |
375,044 |
2010-02-25 |
14,128 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
EVP & Global Head of R&D |
2017-03-01 |
50,688 |
2013-05-13 |
0 |
Premium* |
|
|
Charles River Laboratories Inter... |
CRL |
Director |
2024-05-13 |
12,531 |
2017-08-01 |
0 |
Premium* |
|
|
Rallybio Corp |
RLYB |
Chief Executive Office... |
2022-01-11 |
282,609 |
2021-07-28 |
436,517 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
51 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RLYB |
Rallybio Corp |
Chief Executive Officer |
• • – |
2022-01-11 |
4 |
B |
$10.65 |
$47,882 |
D/D |
4,496 |
282,609 |
2.81 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2008-02-28 |
4 |
D |
$22.55 |
$36,170 |
D/D |
(1,604) |
159,531 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2009-02-26 |
4 |
D |
$12.70 |
$74,130 |
D/D |
(5,837) |
297,581 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice President |
• – – |
2010-02-25 |
4 |
D |
$17.69 |
$19,937 |
D/D |
(1,127) |
375,044 |
0 |
- |
|
| PFE |
Pfizer Inc |
Senior Vice PresidentOfficer |
• – – |
2007-10-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,127 |
|
- |
|
| PFE |
Pfizer Inc |
Senior Vice PresidentOfficer |
• – – |
2007-10-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
109,005 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2014-06-12 |
4 |
OE |
$104.86 |
$2,621,500 |
D/D |
25,000 |
49,426 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2014-11-03 |
4 |
OE |
$104.86 |
$983,063 |
D/D |
9,375 |
33,801 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2015-08-03 |
4 |
OE |
$104.86 |
$5,667,488 |
D/D |
43,500 |
76,393 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2014-05-14 |
4 |
S |
$160.85 |
$574,878 |
D/D |
(3,574) |
24,426 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2014-06-12 |
4 |
S |
$165.88 |
$4,160,565 |
D/D |
(25,000) |
24,426 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2014-11-03 |
4 |
S |
$191.52 |
$1,795,500 |
D/D |
(9,375) |
24,426 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2015-02-10 |
4 |
S |
$171.15 |
$677,956 |
D/D |
(3,897) |
32,219 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2015-03-02 |
4 |
S |
$180.34 |
$66,726 |
D/D |
(370) |
36,949 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2015-05-14 |
4 |
S |
$160.33 |
$650,298 |
D/D |
(4,056) |
32,893 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2015-08-03 |
4 |
S |
$195.19 |
$8,548,418 |
D/D |
(43,500) |
32,893 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2016-02-05 |
4 |
S |
$145.54 |
$14,554 |
D/D |
(100) |
44,756 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2016-02-05 |
4 |
S |
$140.47 |
$283,823 |
D/D |
(2,005) |
42,751 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2016-02-08 |
4 |
S |
$138.02 |
$271,481 |
D/D |
(1,966) |
40,785 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2016-02-29 |
4 |
S |
$138.91 |
$138,910 |
D/D |
(1,000) |
46,785 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2016-05-16 |
4 |
S |
$139.19 |
$570,284 |
D/D |
(4,097) |
42,688 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2017-02-06 |
4 |
S |
$125.69 |
$342,904 |
D/D |
(2,728) |
39,960 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2017-02-09 |
4 |
S |
$126.84 |
$27,524 |
D/D |
(217) |
39,743 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2017-02-27 |
4 |
S |
$131.20 |
$112,832 |
D/D |
(860) |
38,883 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Global Head of R&D |
• – – |
2017-02-28 |
4 |
S |
$131.70 |
$82,313 |
D/D |
(625) |
38,258 |
0 |
- |
|
51 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
